ABVC Stock: Why It Increased Today

By Amit Chowdhry ● Oct 12, 2021
  • The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 2% during intraday trading today. This is why it happened.

The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) – a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology – increased by over 2% during intraday trading today. Investors are responding positively to ABVC Biopharma announcing the execution of a joint venture agreement with Lucidam, a private investment firm based in Tokyo.

And the agreement calls for business development collaboration through BioLite Japan, an existing affiliate of ABVC, that seeks to identify early-stage opportunities in drug development, digital health, and medical device technology. Pursuant to the joint venture agreement, ABVC will retain equity ownership in BioLite Japan at 49% (rather than its pre-agreement 50% ownership) and Lucidam will retain equity ownership in BioLite Japan at 51% (rather than its pre-agreement 50% ownership).

Dr. Toru J. Seo agreed to lead the new joint venture which will be based in Tokyo. And Dr. Seo has vast pharma industry experience in R&D and business development from his previous employment with GSK, Merck, Taisho and Pfizer as its Senior Director and Asia Pacific Lead in the Worldwide Business Development business office.

Under the terms of the deal, BioLite Japan will identify and license New Chemical Entities (NCEs), New Biological Entities (NBEs), diagnostic tools, biomarkers, and medical devices in the early stages of discovery and development anywhere in the world but primarily in Japan. And after conducting any necessary pre-clinical studies, BioLite Japan will transfer the rights of the most promising research to ABVC for further clinical development, regulatory approvals, and subsequent commercialization in exchange for product royalties and/or milestone payments. Plus BioLite Japan will seek potential licensing partners for ABVC’s current pipeline of drug products and medical devices.


“This joint venture should allow us to further ensure access to additional early-stage product candidates that we otherwise would not have access to without this partnership. Dr. Seo has a distinguished career in healthcare and business in Japan and Asia and will play a significant role in expanding our pipeline at an accelerated pace.”

— Dr. Howard Doong, Chief Executive Officer of ABVC

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.